| Designations: |
SNU-398 |
| Depositors: |
J Park |
| Biosafety Level: |
2 [CELLS CONTAIN HEPATITIS B VIRUS ] |
| Shipped: |
frozen |
| Medium & Serum: |
See Propagation |
| Growth Properties: |
mixed adherent and floating |
| Organism: |
Homo sapiens (human) |
| Morphology: |
epithelial
|
| Source: |
Organ: liver
Disease: hepatocellular carcinoma |
| Permits/Forms: |
In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location. |
| |
| Restrictions: |
This line is available under the following restrictions: 1.) The cell line was deposited for research purposes only. Neither the cell line nor products derived from it may be sold or used for commercial purposes. Nor can the cells be distributed to third parties for purpose of sale, or producing for sale, cells or their products. The cells are provided as a service to the research community. They are provided without warranty or merchantability of fitness for a particular purpose or any other warranty, express or implied. 2.) Any proposed commercial use of these cells or products produced by them must first be negotiated with Jae-GaHB-Park, Director, Korean Cell Line Bank, 28 Yongon-dong, Chongno-gu, Seoul, 110-744 Korea. Telephone (02) 760-3380, Fax (02) 742-4727. 3.) In all papers reporting any use of these cells or derived products, a direct reference will be made to the original publication (Int. J. Cancer 62:276-282, 1995). |
| Antigen expression: |
Blood Type O; Rh + |
| DNA Profile (STR): |
Amelogenin: X,Y
CSF1PO: 13
D13S317: 11
D16S539: 10,14
D5S818: 12
D7S820: 10,11
THO1: 7,9
TPOX: 11
vWA: 17,18 |
| Cytogenetic Analysis: |
aneuploid; modal number = 62 |
| Age: |
42 years |
| Gender: |
male |
| Ethnicity: |
Asian |
| Comments: |
SNU-398 was derived in 1990 by J.-G. Park and associates from an anaplastic hepatocellular carcinoma taken from a Korean patient who had been treated by transcatheter arterial embolization with lipoidol plus a combination of doxorubicin and mitomycin-C.
Tumor cells were initially cultured in ACL-4 medium supplemented with 5% heat-inactivated fetal bovine serum.
After establishment, cultures were maintained in RPMI 1640 supplemented with 10% heat inactivated fetal bovine serum.
Grossly, the original tumor was single nodular with perinodular extensions.
Histologically, it was trabecular type.
The cultured cells are multinucleated, and maintain the production of intracytoplasmic hyaline globules as seen in the original tumor.
Hepatitis B virus (HBV) DNA was detected by Southern blot hybridization.
HBV genomic RNA was not expressed. |
| Propagation: |
ATCC complete growth medium: RPMI 1640 medium, 90%; heat-inactivated fetal bovine serum, 10%
|
| Subculturing: |
Subcultivation Ratio: A subcultivation ratio of 1:3 to 1:6 is recommended
Medium Renewal: Every 2 to 3 days
Remove spent medium, add fresh 0.25% trypsin, 0.03% EDTA solution, rinse and remove trypsin.
Add fresh trypsin solution (1 to 2 ml) and let the culture sit at room temperature (or at 37C) until the cells detach.
Add fresh medium, aspirate and dispense into new flasks. |
| Preservation: |
Culture medium, 95%; DMSO, 5% |
| Doubling Time: |
39 hrs |
| References: |
22872: Park JG, et al. Characterization of cell lines established from human hepatocellular carcinoma. Int. J. Cancer 62: 276-282, 1995. PubMed:7543080 |
|
